THE RISING REALM AMONGST STAKEHOLDERS IN PURSUIT OF ALTERNATIVE THERAPIES TO ANTIBODIES THERAPIES
Aptamers have gained a lot of momentum in the past decade. It is worth highlighting that in 2005, Macugen became the first and the only USFDA approved aptamer drug for treating age-related macular degeneration (AMD).
It has been reported that more than 15 million people in the US suffer from AMD alone with 200,000 cases annually across North America.  This indicates a high unmet need of patients thus, paving a way for aptamer-based solutions due to their advantages over traditional antibody-based therapies.
This has led to rapid developments in the domain which can be attributed to various factors, such as number in the number of clinical trials, increased awareness about advantages offered by Aptamers as compared to antibodies, rise in the investment in the pharmaceutical research and development, along with rise in prevalence of chronic and rare diseases have contributed to the increase in the demand for Aptamers-based therapeutics and diagnostic solutions. 
Browse Report:  https://www.rootsanalysis.com/reports/a … arket.html
Aptamers are developed through the SELEX process and over the years these have become primary tools for aptamer synthesis.
Over the past three decades, since the invention of SELEX by Larry Gold and Jack William in the 1990, the technology has seen several modifications to streamline and standardized aptamer-isolation process. These modifications substantially enhance efficiency / optimization to yield best possible aptamer or reduce the duration of the process.
Other noteworthy developments in modifications of Aptamers, include the addition of functional units of non-nucleic origin and nucleotide modifications, which further improves aptamer performance.
Get Customized Report @ Aptamers Market by Industry Trends and Global Forecasts, 2022-2035
SELEX has evolved a lot and a brief history of its evolution has been mentioned below:
Steps involved in the SELEX process:
• Library Generation: Oligonucleotide library is created containing single-stranded nucleic acids having random sequences flanked by binding sites.
• Binding and Separation: Target molecule is incubated along with the oligonucleotide library allowing for nucleic acids to bind to them resulting in the formation of Aptamers. The remaining unbound nucleic acids are filtered out of the solution and through the process of elution the bound nucleic acid is separated from the target.
• Amplification: The nucleic acids separated through the process of elution are then used to create a new library using the Polymerase Chain Reaction (PCR), this provides a new library that can be utilized for new round of SELEX thus, improving the quality of Aptamers synthesized
ADVANTAGES OF APTAMERS
For many years, researchers have been raising and modifying antibodies to detect specific circulating proteins and develop targeted therapeutic agents.  While antibodies are highly effective for a wide range of applications, there are unique aptamer advantages that can overcome some difficult scientific challenges.
Targets small molecules: Flexibility of Aptamers offer wider applications as they can be developed against molecules as small as 60 Daltons this means Aptamers can target molecules that are ten times smaller than antibody targets. Currently, Aptamers for small molecule drugs, peptides, dyes and viral particles have been developed successfully.
Pursue toxic and non-immunogenic targets: Aptamer development process does not involve animals or living cells thus, making it possible to select Aptamers for toxic compounds such as zootoxins and pathogenic bacteria. Additionally, Aptamers do not require immune response and binding of tertiary aptamer structures to target molecules.
Penetrate tissues and cells: Due to their small size (30-80 nucleotides), they have enhanced ability to penetrate tissues thus, allowing them to reach specific targets efficiently. Some Aptamers are able to enter cells without external assistance.
Request for Sample: https://www.rootsanalysis.com/reports/A … ample.html
Key Questions Answered
• Who are the key players engaged in the development of aptamer-based therapeutics and technologies?
• Which are the key drugs being evaluated across early and late stages of development?
• Which companies are actively involved providing aptamer-based services?
• What is the evolving trend of publications focused on aptamer-based therapeutics and technologies?
• What type of partnership models are commonly adopted by industry stakeholders?
• Who are the key investors in this domain?
• Which companies are actively filing patents to drive innovation in this niche segment?
• What are the different initiatives undertaken by start-up players for the development of aptamer-based technologies in the recent past?
• How is the current and future opportunity likely to be distributed across key market segments?
Inquiry before Purchasing: Aptamers Market by Industry Trends and Global Forecasts, 2022-2035
Read Our Latest Press Release:
The biosensors market focused on drug discovery and development is projected to grow at an annualized rate of 9% during the period 2022-2035, claims Roots Analysis
The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%, till 2035, claims Roots Analysis
The oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis
The opportunity within the lyophilization services market for biopharmaceuticals is projected to grow at an annualized rate of ~7%, till 2035, claims Roots Analysis
The intranasal therapeutics and drug delivery systems market is projected to grow at a CAGR of 18%, claims Roots Analysis

Visit for More Insights: https://www.rootsanalysis.com/reports.html
Read Our Latest Press Release: https://www.rootsanalysis.com/press-releases.html
Latest Blogs On Healthcare Industry: https://www.rootsanalysis.com/blog/